[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f4-Oe2WLU9Ymspos6KvtvN5mPlXhTcMqWMV93tpUBnmY":8,"$f7lIaEJ0wRuWaou2-Z2rY2zYNzjS5LoU51apZpO2ZBQ0":55,"$f8M1tntrfgsLFpQYM0eQz1RuLJz32yxQW7qQU6ndd-Xk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},47033,867180,[],"https://ystcdn.venuertc.com/medical/ystApp/dQ4Pxlwso3rc1NhluBbxmQ6HzjnaGqJP.png","王志刚","山西省汾阳医院","妇科","主治医师",23,0,"二期食管低分化鳞癌治疗常用药品安全用药指南","","https://ystcdn.venuertc.com/venue/AI/c000cbae-3dde-4494-8fd5-805108a883ae.jpg","\u003Ch2 id=\"material_title\" class=\"cancer-drug-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二期食管低分化鳞癌治疗常用药品安全用药指南\u003C/h2>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #eef6fa 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、核心药品概览🌱\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cp>在二期食管低分化鳞状细胞癌的治疗中，主要会用到紫杉醇、铂类药物（如顺铂、卡铂）和免疫检查点抑制剂（比如派姆单抗、纳武利尤单抗）。这些药品各具特点，协同作用时能够提升治疗效果。本文将系统梳理这几类药品的成分特点、使用方法、常见问题及注意事项，让您快速把握7个安全用药重点，避免不必要的风险。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f3efe0 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、成分和剂型解析🔬\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>紫杉醇（Paclitaxel）\u003C/strong>：微管抑制剂，阻止肿瘤细胞分裂，常见剂型为静脉注射液。常见规格有30mg/支、100mg/支。\u003C/li>\n      \u003Cli>\u003Cstrong>顺铂（Cisplatin）/卡铂（Carboplatin）\u003C/strong>：作用于DNA，抑制细胞复制。以注射用浓溶液为主，顺铂 10mg/20mg/50mg/100mg，卡铂常见规格为50mg、150mg等。\u003C/li>\n      \u003Cli>\u003Cstrong>免疫检查点抑制剂（如帕博利珠单抗 Pembrolizumab、纳武利尤单抗 Nivolumab）\u003C/strong>：单克隆抗体，重启免疫系统清除异常细胞，规格为100mg/4mL等，静脉滴注给药。\u003C/li>\n    \u003C/ul>\n    \u003Cp>这些药品均为处方药，只能注射给药，需专业医疗人员操作。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #e9f5f0 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、药品作用机制一览💡\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>紫杉醇\u003C/strong>：稳定细胞骨架阻止微管去聚合，使肿瘤细胞停留在分裂期，细胞无法分裂继而死亡。\u003C/li>\n      \u003Cli>\u003Cstrong>铂类药物\u003C/strong>：与DNA结合，干扰遗传物质复制过程，导致细胞损伤乃至凋亡。\u003C/li>\n      \u003Cli>\u003Cstrong>免疫检查点抑制剂\u003C/strong>：阻断PD-1/PD-L1信号，让T细胞重新识别并攻击不正常细胞。\u003C/li>\n    \u003C/ul>\n    \u003Cp>三类药品联用能够从不同环节打击异常细胞，提升效果。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #efe9f2 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、使用方法和正确操作📎\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Ch3 class=\"cancer-drug-mini-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1. 紫杉醇的安全用药细节\u003C/h3>\n    \u003Cul>\n      \u003Cli>应在医院静脉滴注给药，由专业护士操作。\u003C/li>\n      \u003Cli>根据体表面积、肝功能等专科参数制定剂量。\u003C/li>\n      \u003Cli>输注时间一般为1~3小时，不宜过快，避免过敏风险。\u003C/li>\n      \u003Cli>首次用药需密切监测：部分患者会有过敏反应，需提前用抗过敏药物预处理。\u003C/li>\n    \u003C/ul>\n    \u003Ch3 class=\"cancer-drug-mini-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2. 铂类药物的注意点\u003C/h3>\n    \u003Cul>\n      \u003Cli>医生会评估肾功能决定用药种类及剂量——顺铂对肾脏更敏感。\u003C/li>\n      \u003Cli>建议大剂量顺铂用药同时补充足够液体，防止肾损伤。\u003C/li>\n      \u003Cli>注射时需避免与铝制品器具接触（特别是顺铂），以防药品失效。\u003C/li>\n    \u003C/ul>\n    \u003Ch3 class=\"cancer-drug-mini-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3. 免疫检查点抑制剂的应用要求\u003C/h3>\n    \u003Cul>\n      \u003Cli>遵医嘱按周期静脉滴注，用药前后需评估相关指标（如肝、肾、甲状腺功能）。\u003C/li>\n      \u003Cli>有些药品允许与其他化疗药物联合用药，但方案需由专科医生个体化制定。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #e7ecf9 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、常见药物相互作用 ⚠️\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>紫杉醇\u003C/strong>：不可与某些抗真菌药如酮康唑同时使用，易增不良反应。与环孢素、红霉素、地尔硫䓬等并用时，可能影响药物代谢，需调整剂量。\u003C/li>\n      \u003Cli>\u003Cstrong>顺铂/卡铂\u003C/strong>：配伍时严禁与含铝的器械及药液混合；与利尿剂、某些抗生素合用会加重肾损伤。\u003C/li>\n      \u003Cli>\u003Cstrong>免疫检查点抑制剂\u003C/strong>：应用激素类药物或免疫抑制剂时可能影响药效（仅在特殊情况下可并用），未获医学许可不得擅自加疗。\u003C/li>\n    \u003C/ul>\n    \u003Cp>正确做法：用药前主动告知医生近期服用的所有药物，包括保健品、中药，避免相互作用发生。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f6f2e9 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、特殊人群与剂量调整👵🧑‍⚕️\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>老年人\u003C/strong>：肝、肾功能常减退，要定期复测各项指标。用药起始剂量宜偏低。\u003C/li>\n      \u003Cli>\u003Cstrong>肝肾功能不全\u003C/strong>：紫杉醇、铂类药物需据肝、肾生化指标调整。严重损伤时应暂停或换药。\u003C/li>\n      \u003Cli>\u003Cstrong>孕妇、哺乳期妇女\u003C/strong>：已知可致胎儿畸形，禁止怀孕及哺乳期间使用。\u003C/li>\n      \u003Cli>\u003Cstrong>儿童用药\u003C/strong>：紫杉醇/顺铂等未明确儿童安全性，绝不可自行试用。\u003C/li>\n    \u003C/ul>\n    \u003Cp>有位高龄女患者联合用药效果良好，通过肝肾指标调整剂量，有效减少不适，提高耐受性。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #e8f4f4 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、不可忽视的不良反应及处理方法🌡️\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>紫杉醇\u003C/strong>：最常见为白细胞减少（约50%以上患者），用药中需动态监测；部分患者会有周围神经病变，如肢体麻木、刺痛感。出现严重不良反应需暂停或调整剂量。\u003C/li>\n      \u003Cli>\u003Cstrong>铂类药物\u003C/strong>：顺铂易致肾损伤和耳毒性（如听力下降）；卡铂较为温和，但仍须监测肾功能。发现恶心呕吐、尿少或听力异常要及时就诊。\u003C/li>\n      \u003Cli>\u003Cstrong>免疫检查点抑制剂\u003C/strong>：有2-10%概率出现免疫相关副作用，如肝功能波动、皮疹、乏力等，部分患者需暂时或永久停药，并给予激素类药物干预。\u003C/li>\n    \u003C/ul>\n    \u003Cp>正确做法：每次用药后密切关注血象、生化、体感变化，定期复查。发现异常及时联系医疗团队，切勿自行停药或加药。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f3ece7 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、药品储存、运输与有效期⏳\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>紫杉醇、铂类、免疫抑制剂均为冷藏产品，应储存在2~8℃冰箱内，不可冷冻。\u003C/li>\n      \u003Cli>勿私自携带、运输，避免阳光直射、高温环境。运输途中建议带冰袋隔离。\u003C/li>\n      \u003Cli>开封后如发现药液浑浊、沉淀、变色，需废弃不用。\u003C/li>\n      \u003Cli>过期药品切勿随意丢弃，最好交由药房或医疗机构专业回收。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #e8f1fa 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">九、用药应急举措与日常管理🗒️\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>漏服\u003C/strong>：此类药物均为医院集中制剂，出现漏用需及时告知就诊医生，不可擅自补用。\u003C/li>\n      \u003Cli>\u003Cstrong>过量\u003C/strong>：如一次性输注超量，可能出现严重骨髓抑制、肝肾损害等并发症，应立刻就医，采取对症支持治疗。\u003C/li>\n      \u003Cli>日常合理安排复查、检测，有助于早发现潜在问题。\u003C/li>\n    \u003C/ul>\n    \u003Cp>用药期间保持充足营养、规律作息，有助于机体耐受药物、减少副作用。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f2f7ec 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十、用药案例分享🧬\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>一位老年女性在使用紫杉醇联合免疫药物维持治疗时，因及时调整剂量与联合监测白细胞水平，顺利完成疗程，未因不良反应而中断方案。\u003C/li>\n      \u003Cli>临床配伍时如未注意顺铂与含铝注射器具的分离，发现药效下降，因此强调所有药品配伍都严格记录与专用器械分开。\u003C/li>\n    \u003C/ul>\n    \u003Cp>实际应用中个体差异巨大，经验需配合专科医生评估。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #eaf3f1 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十一、数据简析与循证参考📊\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cul>\n      \u003Cli>说明书提示：紫杉醇单药相关白细胞减少发生率达50%以上（Bristol-Myers Squibb, 2021）。\u003C/li>\n      \u003Cli>一项随机对照研究显示，紫杉醇联合免疫治疗2年后无进展生存率显著提升（Shah et al., Lancet Oncology, 2021）。\u003C/li>\n      \u003Cli>免疫检查点抑制剂相关严重副作用发生率约2-10%（Postow et al., New England Journal of Medicine, 2018）。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f5f7ee 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十二、总结与安全用药建议📝\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Cp>紫杉醇、铂类药物和免疫检查点抑制剂协同，可提升治疗效果，也带来一定不良反应风险。掌握安全用药技巧，严格按方案操作，关注药物相互作用、特殊人群剂量及不良反应监测，能最大限度保障治疗顺利进行。每次用药遇到疑问，都建议与主治团队充分沟通。安全、规范是正确用药的关键，希望本文内容让您用得安心、放心。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 文献引用部分 -->\n\u003Cdiv class=\"cancer-drug-section\" style=\"background: linear-gradient(90deg, #f3f4ec 0%, #f5f5f5 100%);\">\n  \u003Ch2 class=\"cancer-drug-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n  \u003Cdiv class=\"cancer-drug-content\">\n    \u003Col>\n      \u003Cli>Bristol-Myers Squibb. (2021). Paclitaxel (Taxol) Prescribing Information. Retrieved from \u003Ca href=\"https://packageinserts.bms.com/pi/pi_taxol.pdf\" target=\"_blank\" rel=\"noopener\">https://packageinserts.bms.com/pi/pi_taxol.pdf\u003C/a>\u003C/li>\n      \u003Cli>Shah, M.A., et al. (2021). Pembrolizumab versus chemotherapy as second-line therapy in advanced esophageal cancer: KEYNOTE-181. \u003Cem>Lancet Oncology\u003C/em>, 22(3), 288-298. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33545035/\" target=\"_blank\" rel=\"noopener\">https://pubmed.ncbi.nlm.nih.gov/33545035/\u003C/a>\u003C/li>\n      \u003Cli>Postow, M.A., Sidlow, R., & Hellmann, M.D. (2018). Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. \u003Cem>New England Journal of Medicine\u003C/em>, 378(2), 158-168. \u003Ca href=\"https://www.nejm.org/doi/full/10.1056/NEJMra1703481\" target=\"_blank\" rel=\"noopener\">https://www.nejm.org/doi/full/10.1056/NEJMra1703481\u003C/a>\u003C/li>\n      \u003Cli>National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology—Esophageal and Esophagogastric Junction Cancers. \u003Ca href=\"https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf\" target=\"_blank\" rel=\"noopener\">https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf\u003C/a>\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.cancer-drug-title {\n  font-size: 36px;\n  color: #19385d;\n  text-align: center;\n  margin: 32px 0 18px 0;\n  font-weight: bold;\n  letter-spacing: 1px;\n  line-height: 1.2;\n}\n.cancer-drug-section {\n  margin: 20px 0 32px 0;\n  border-radius: 8px;\n  box-shadow: 0 2px 8px rgba(150,179,194,0.06);\n  padding-top: 0px;\n  padding-left: 0px;\n  max-width: 900px;\n  margin-left: auto;\n  margin-right: auto;\n}\n.cancer-drug-subtitle {\n  font-size: 26px;\n  background: rgba(195,214,230,0.07);\n  border-radius: 8px 8px 0 0;\n  margin: 0;\n  padding: 18px 36px;\n  color: #184273;\n  font-weight: 600;\n  letter-spacing: 0.5px;\n  border-bottom: 1px solid #e1e6eb;\n  line-height: 1.35;\n}\n.cancer-drug-content {\n  padding: 28px 36px 24px 36px;\n  font-size: 18px;\n  color: #32475b;\n  line-height: 1.7;\n  background: rgba(255,255,255,0.90);\n  border-radius: 0 0 8px 8px;\n}\n.cancer-drug-content ul {\n  padding-left: 22px;\n  margin-bottom: 10px;\n}\n.cancer-drug-content li {\n  margin-bottom: 6px;\n}\n.cancer-drug-content p {\n  margin: 10px 0 10px 0;\n}\n.cancer-drug-mini-title {\n  margin: 18px 0 8px 0;\n  font-weight: bold;\n  color: #203c54;\n  font-size: 20px;\n  letter-spacing: 0.3px;\n}\n/* 美化引用链接 */\n.cancer-drug-content a {\n  color: #3a6be0;\n  text-decoration: underline;\n  word-break: break-all;\n}\n.cancer-drug-content a:hover {\n  color: #1c3e72;\n}\n@media (max-width: 700px) {\n  .cancer-drug-title {\n    font-size: 24px;\n    padding: 0 10px;\n  }\n  .cancer-drug-section {\n    padding: 0;\n    max-width: 100%;\n    margin: 12px 0;\n  }\n  .cancer-drug-subtitle {\n    font-size: 19px;\n    padding: 12px 10px;\n  }\n  .cancer-drug-content {\n    padding: 14px 12px 12px 12px;\n    font-size: 16px;\n  }\n  .cancer-drug-mini-title {\n    font-size: 17px;\n  }\n}\n\u003C/style>\n\n","\u003Ch2 id=\"material_title\" class=\"cancer-drug-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0",392,"2025-07-07 17:49:55","食管低分化鳞癌, 紫杉醇, 铂类药物, 免疫检查点抑制剂, 安全用药, 不良反应, 药物相互作用, 特殊人群用药","掌握二期食管低分化鳞癌治疗的核心药品及其使用方法，了解不良反应、药物相互作用和特殊人群用药建议，确保安全用药经验。适合患者及其家属参考，专业权威，助力治疗效果优化。","2025-07-08 21:48:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]